Kornimate/medical-research-clean huggingface dataset:
covid-19 on disease activity in radiologically isolated syndrome cohort

Conditions: Multiple Sclerosis; COVID-19

Summary: the radiologically isolated syndrome (ris) is defined as incidental magnetic resonance imaging (mri) abnormalities fulfil the criteria for dissemination in space, suggestive of multiple sclerosis. nowadays, mandatory vaccination in patients with multiple sclerosis (ms) is widely recommended. regarding covid19, the absence of specific warnings led to the proposal of vaccination in patients with inflammatory diseases of the central nervous system. we aimed to evaluate if covid19 vaccination or infection increased the risk of clinical conversion to multiple sclerosis or evidence of disease activity (eda) in a cohort of ris subjects.


Eligibility criteria:
inclusion criteria: * patients belong to the risc cohort; * totally vaccinated ou partially vaccinated patient * vaccination status known exclusion criteria: * presented a first clinical event before the covid19 vaccination
hiv self-testing and uptake and retention of prep among older adolescent msm and tgw

Conditions: Men or Transgender Women Who Have Sex With Men

Summary: this will be a prospective study that will enroll up to 600 older adolescent msm and tgw from community-based clinics in bangkok, chonburi, chiang mai, and songkhla.

all eligible participants will be followed up at month 3, 6, 9, and 12; month 6 and 12 will be mandatory clinic visits, while month 3 and 9 will be either clinic or a virtual visits. for participants accepting prep, additional follow-up visit at month 1, 2, 4, and 5 will be appointed; all visits will be either clinic or virtual visits. study sites the study will take place at the following community-based clinics: 1. swing dic, bangkok, thailand 2. rsat dic, bangkok, thailand 3. swing dic, chonburi, thailand 4. sister dic, chonburi, thailand 5. caremat dic, chiang mai, thailand 6. mplus dic, chiang mai, thailand 7. rsat dic, songkhla, thailand

Eligibility criteria:
inclusion criteria: 1. thai nationality 2. age 15-19 years old 3. men or transgender women who have sex with men 4. hiv-negative at the time of screening 5. have at least one of the following risks for hiv acquisition in the past 6 months: 1. any unprotected receptive anal sex with a male partner 2. more than 5 male partners, regardless of condom use and serostatus 3. has had a bacterial sexually transmitted infection (sti) 4. any injected drug use 6. calculated creatinine clearance (crcl) ≥ 75 ml/min, as estimated by the cockcroft- gault equation 7. alanine aminotransferase (alt) ≤ 2.5 x uln 8. have signed the informed consent form exclusion criteria: 1. hiv-positive 2. hepatitis b infection as indicated by positive hepatitis b surface antigen (hbsag) test at time of screening 3. known allergy/sensitivity to tenofovir or emtricitabine
usefulness of smartphone application for improving nutritional status of pancreatic cancer patients

Conditions: Pancreatic Cancer

Summary: malnutrition of hospitalized patients is reported in the range of 20-60% according to the definition and assessment method of malnutrition. in particular, the incidence of malnutrition in cancer patients is high up to 30-85%. gastrointestinal disease is related to the digestion and absorption of nutrition therefore malnutrition rate of those patients is relatively high. careful management of nutrition support is needed. malnutrition causes dysfunction of the mesenteric membrane, immune function impairment, decreased function of major organs such as liver, kidney and heart and alteration in pharmacodynamics. it could also increase infection rate and complications of chemotherapy, delay recovery time, so that increase morbidity, mortality and length of hospital stay. proper nutrition management reduces malnutrition prevalence and medical costs of hospitalized patient, therefore nutrition screening and evaluation is necessary. the recent spread of smartphones has made it easier to record and evaluate meals, which are used in the diet market for weight loss through meal records and feedback based on smartphone applications. this approach is also expected to benefit patients with gastrointestinal cancer, where proper nutrition and feedback are important. in particular, pancreatic cancer, the worst intractable cancer of mankind, is digestive cancer with the most severe muscle mass reduction and nutritional deterioration after diagnosis.


Eligibility criteria:
inclusion criteria: 1) among patients with pancreatic cancer who visited severance hospital of yonsei university 1. patients who received the explanation from the investigator and agreed to the written consent of the subject 2. men or women aged 20 to 70 2) first diagnosed with pancreatic cancer within 3 months 3) patients scheduled to undergo first-line chemotherapy after the diagnosis of pancreatic cancer exclusion criteria: 1. those who have or had a history of abdominal surgery within the past 1 year 2. those who have an acute illness (pneumonia, sepsis, shock, etc.) and have an infection at the time of registration 3. chronic liver disease and chronic obstructive pulmonary disease 4. patients with nutrient absorption disorder due to gastrointestinal mucosal diseases (ulcerative colitis, crohn's disease, acute and chronic diarrhea, etc.) 5. severe disease patients (heart failure, liver failure, kidney failure and hemodialysis, etc.) 6. those who are pregnant or breastfeeding 7. those who have used steroids within the last one month 8. patients diagnosed of peritoneal seeding or suspected gi obstructive sign 9. those who are already taking nutritional supplements
a comparative analysis of intertransverse nerve block and paravertebral nerve block in endoscopic hepatectomy

Conditions: Pain

Summary: this study aims to compare the analgesic effect of intertransverse nerve block and paravertebral nerve block after endoscopic hepatectomy, evaluate its effectiveness and safety, and provide new ideas and clinical basis for postoperative pain management of liver surgery.

this study was a prospective, double-blind, randomized controlled trial. patients who were eligible for laparoscopic partial liver resection in our center were included, with intertransverse nerve block as the experimental group and paravertebral nerve block as the control group. through the analysis of postoperative pain score 30min to 24h, the number of effective analgesic pump compressions within 24h, the amount of analgesic drugs used, complications and other data, to evaluate the efficacy and safety of intertransverse nerve block in patients undergoing laparoscopic partial liver resection.

Eligibility criteria:
inclusion criteria:1: 1.18-80 years old adult, bmi\<27.9kg/m2 2: 2. american society of anesthesiologists asa grade i-iii 3: 3. patients with laparoscopic partial liver resection such as liver tumors 4: 4. willing to participate in this study and sign the informed consent form - exclusion criteria: 1. 1. the patient or family member refuses to sign the informed consent form 2. 2. blood coagulation dysfunction, local infection 3. 3. those who have communication, communication disorders or mental abnormalities 4. 4. patients with severe heart, pulmonary and renal insufficiency or patients with central system diseases 5. 5. for any reason, it cannot be matched with the study or the researcher believes that it is not appropriate to be included in this experiment. -
the resteaze ambulatory sleep monitor for detection of leg movements during sleep in adults and children with a sleep disturbance

Conditions: Sleep

Summary: this observational study will test and evaluate the resteaze ambulatory sleep monitor for the detection and classification of leg movements during sleep (lms) and other sleep measures.


Eligibility criteria:
inclusion criteria: * ages between 5 -75 * general good health and ambulatory * sleep complaint or other diagnosis that affects sleep (e.g. adhd) with likely concomitant abnormal lms requiring either hst or psg * reports no significant problems sleeping in a new bed and bedroom away from home * (if applicable) parent or guardian available to spend the night with the child during the sleep study exclusion criteria: • amputation that would preclude use of wrist actigraph or the resteaze device
the efficiency of the central venous catheter care protocol

Conditions: Stem Cell Transplant Complications; Central Venous Catheter Exit Site Infection

Summary: the study aims to evaluate the effectiveness of a central venous catheter (cvc) care protocol, which was created using current guidelines, research results, and expert opinions, on developing cvc-related bloodstream infection in patients with hematopoietic stem cell transplantation (hsct) until discharge.

hematopoietic stem cell transplantation (hsct) is one of the important treatment approaches that prolongs survival in patients with hematological malignancies, immunodeficiency and some solid tumors. despite advances in the treatment process, reasons such as recurrence of the underlying disease, organ toxicities and infectious complications adversely affect treatment success. reasons such as high-dose chemotherapy, frequent blood sampling, stem cell reinfusion, and total parenteral nutrition applied to hsct patients increase the need for central venous catheter insertion. although these tools are often necessary and useful in the bone marrow transplantation process, they also bring mechanical, embolic, and infectious complications. central venous catheters (cvc) are one of the main applications of modern clinical treatment. reasons such as high-dose chemotherapy, frequent blood sampling, stem cell reinfusion, and total parenteral nutrition applied to hsct patients increase the need for central venous catheter insertion. although these tools are often necessary and valuable in the bone marrow transplantation process, they also bring mechanical, embolic, and infectious complications. the study aims to evaluate the effectiveness of a central venous catheter (cvc) care protocol, created using current guidelines, research results, and expert opinions, on developing cvc-related bloodstream infection in patients with hematopoietic stem cell transplantation (hsct) until discharge. this research is a pretest-posttest quasi-experimental clinical study. it is conducted with 60 patients between january 2022 and december 2023. the data is collected with patient information form and daily patient evaluation chart. no application will be made to 30 patients in the control group, and catheter care will be provided to the patients of the intervention group in line with the cvc care protocol created by the researchers.

Eligibility criteria:
inclusion criteria: * being hospitalized by the medical oncology clinic at in a training and research hospital to become an autologous hsct, * the patient has an 8f-size, two-lumen temporary cvc, * over 18 years of age * there is no communication problem, * agreeing to participate in the research voluntarily after being informed about the study, exclusion criteria: * using a vascular access method other than an 8f size two-lumen temporary cvc in the patient, * refusal to participate in the research voluntarily after being informed about the study, * identification of a different focus of infection in the patient.

Keywords: central venous catheter hematopoietic stem cell transplantation
reduction of antibiotic therapy by biomakers in patients with cap episodes (reduce study)

Conditions: Community Acquired Pneumonia

Summary: the purpose of this study is to evaluate two different treatment strategies in patients admitted to hospital with community acquired pneumonia. the investigators hypothesize treatment according to both procalcitonin (pct) and c-reactive protein (crp) will be effective in reducing the length of antibiotic treatment.


Eligibility criteria:
inclusion criteria: male and female patients with a diagnosis of cap and all criteria listed below: 1. age 18 or above, no upper age limit will be employed. 2. patients must require hospitalisation. 3. clinical presentation of an acute illness with one or more of the following symptoms: 1. temperature ≥ 38.0 ⁰c (100.4°f) 2. dyspnoea 3. cough (with or without expectoration of sputum) 4. chest pain 5. malaise or fatigue 6. myalgia 7. gastro-intestinal symptoms 8. rales, rhonchi or wheezing 9. egophony or bronchial breath sounds 4. new consolidation(s) on the chest radiograph. 5. written informed consent obtained. 6. (pre-event) life expectancy \> 30 days exclusion criteria: subjects presenting with any of the following will not be included in the study: 1. (severe) immunosuppression (e.g. hiv infection, chemotherapy, use of immunosuppressants). 2. active neoplastic disease. 3. obstruction pneumonia (e.g. from lung cancer). 4. aspiration pneumonia. 5. pneumonia that developed within 8 days after hospital discharge. 6. unable and/or unlikely to comprehend and/or follow the protocol. 7. pregnant and/or lactating women. 8. other infection that requires treatment with antibiotics
a study of pegylated rhg-csf as support to advanced non-small-cell lung cancer (nsclc) patients receiving chemotherapy receiving chemotherapy

Conditions: NSCLC; Neutropenia; Febrile Neutropenia

Summary: neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy. a newly pegylated rhg-csf was independently developed by jiangsu hengrui medicine co., ltd, china. phase 1a, 1b and phase 2 trials have shown that pegylated rhg-csf has decreased renal clearance, increased plasma half-life, and prolonged efficacy in compare with ﬁlgrastim. the purpose of this study is to determine the safety and effectiveness of pegylated rhg-csf in preventing neutropenia following chemotherapy in patients with advanced nsclc.


Eligibility criteria:
inclusion criteria: * investigator diagnosis of staged iii or iv nsclc * age 18 to 70 years * ecog performance status ≤ 1 * chemotherapy naïve * body weight ≥ 45kg * hemoglobin ≥ 100g/l; white blood cell ≥ 4.0×109/l; absolute neutrophil count ≥1.5 × 109/l; platelet count ≥ 100 × 109/l * alanine transarninase ≤1.5×uln; aspartate aminotransferase ≤1.5×uln; serum creatinine ≤1.5×uln; total bilirubin ≤1.5×uln exclusion criteria: * history of systematic chemotherapy or radical radiation therapy * prior bone marrow or stem cell transplantation * received systemic antibiotics treatment within 72 h of chemotherapy * pregnancy or lactation

Keywords: neutropenia febrile neutropenia chemotherapy
er/la opioid analgesics - surveillance monitoring of state medical examiner databases

Conditions: Opioid-related Disorders; Opioid Addiction; Narcotic Abuse; Drug Abuse

Summary: in april 2011, the u.s. food and drug administration (fda) determined that a class-wide risk evaluation and mitigation strategy (rems) for all extended-release (er) and long-acting (la) opioid medications was necessary to support national efforts to reduce serious adverse outcomes resulting from opioid abuse. this study will evaluate trends before and after the er/la rems implementation for changes in mortality rates associated with prescription opioids utilizing state medical examiner databases from multiple states. databases from 2005 through the most recent year available will be obtained.


Eligibility criteria:
inclusion criteria: * fatalities associated with prescription opioids in several states during 2005-2015 (or later). exclusion criteria: * none
communication model to self-care - regardless of health literacy

Conditions: Chronic Disease

Summary: healthcare systems all over the world are developing in a way that compels patients to become more active in the management of their own health and disease - a development that changes the role of modern patients and the skills needed to navigate the healthcare system. demographic changes resulting in more elderly people have led to increases in the burden of chronic diseases and put pressure on increasingly scarce healthcare resources. one strategy for overcoming this burden is to reduce the utilization of healthcare resources in the secondary sector by reducing the length of stay and placing more health care services in the primary sector, thus allowing more rehabilitation actions, where the goal is to have patients take control of their own life situation and health. this means that community nurses are compelled to strengthen citizens' ability to manage their own disease and everyday life. a focus on health literacy and its significance for everyday life with chronic disease can increase the probability of citizens' acquiring the instructions and guidance given by community nurses, and thus strengthen the ability for self-care and self-rehabilitation. in line with this, a systematic interactive communication model has been developed to help strengthen self-care for citizens with chronic diseases. for more information, see the description of the intervention above. the study is targeted citizens, who receive community nursing. a possible benefit of participating is an improvement of quality of life in everyday life for citizens receiving community nursing. no risks related to participation in the study. the study is run from four community nursing districts in aalborg municipality. the development of the intervention was initiated in september 2019, and the study is expected finalised in july 2022. this study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.


Eligibility criteria:
inclusion criteria: * ability to give informed consent * age \> 18 * fixed residence in aalborg municipality * receives home healthcare services for a period of more than three months * ability to speak, read and write danish exclusion criteria: * diagnosed with a severe psychiatric disease * diagnosed with dementia or other severe cognitive impairments * terminal * unable to understand and speak danish * pregnancy * participation in other studies that could effect the primary outcome of this study

Keywords: health literacy nursing self-care primary care
the effect of ganglion sphenopalatine block (gsp-block) versus placebo on postdural puncture headache

Conditions: Postdural Puncture Headache; Sphenopalatine Ganglion Block

Summary: the purpose of this study is to evaluate the effect of the ganglion sphenopalatine block (gsp block) on postdural puncture headache.

adult patients with postdural puncture headache will be enrolled in the study. the patients will be randomised to receive a ganglion sphenopalatine block (gsp-block) with either local anesthetic (lidocaine + ropivacaine) or placebo (isotone nacl). primary outcome is hyperactivity in the sphenopalatine ganglion assessed by pain intensity (0-100mm on a visual analogue scale, vas) of the postdural headache in standing position 30 minutes after block. if the patients in the timeframe of 1 hour to 1 week after block does not achieve remission (vas \<30mm while standing) they will be offered a "rescue gsp-block" defined as a new gsp-block with "open-label" local anesthetic and if continued lack of remission at least 1 hour thereafter then an epidural blood patch will be offered.

Eligibility criteria:
inclusion criteria: * age \> 18 years * patients with postdural puncture headache defined as moderate to severe postural headache (vas \>= 30mm) after lumbar puncture or accidental dural puncture during epidural insertion with an onset within 3 days following the puncture. * lack of headache remission within 1 day after dural puncture and after treatment with fluids, caffeine and paracetamol * patients who have given their written informed consent for participation in the study after fully understanding the protocol content and limitations. exclusion criteria: * patients who cannot cooperate to the study * patients who does not understand or speak danish * allergy to the drugs used in the study * has taken opioids within 12 hours prior to intervention
iron oligosaccharide in inflammatory bowel disease subjects with iron deficiency anaemia

Conditions: Inflammatory Bowel Disease

Summary: the purpose of the trial is to demonstrate that intravenous iron oligosaccharide is non-inferior to oral iron sulphate in reducing iron deficiency anaemia secondary to inflammatory bowel disease (ibd), evaluated as the ability to increase haemoglobin (hb).

the study is designed to determine the effects of an investigational drug monofer in subjects with inflammatory bowel disease (ibd) (an intestinal disease characterized by swelling, redness and sometimes ulcers in intestine) and with iron deficiency anaemia (ida) (anaemia is a condition characterized by deficiency of blood in the body).

Eligibility criteria:
inclusion criteria: subjects with a diagnosis of ibd with iron deficiency anaemia will be included if they meet all of the following criteria: 1. men and women, aged more than 18 years. 2. subjects diagnosed with inflammatory bowel disease and mild to moderate disease activity (defined as a score of less than or equal to 5 on the harvey-bradshaw index for crohn's disease and a mayo score (subscore without endoscopy) of less than or equal to 6 for ulcerative colitis). 3. hb \<12.0 g/dl (7.45 mmol/l). 4. transferrin saturation (tfs) \<20 %. exclusion criteria: 1. anaemia predominantly caused by other factors than iron deficiency anaemia. 2. iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis). 3. drug hypersensitivity (i.e. previous hypersensitivity to iron dextran or iron mono- or disaccharide complexes or to iron sulphate). 4. known hypersensitivity to any excipients in the investigational drug products. 5. subjects with a history of multiple allergies. 6. active intestinal tuberculosis. 7. active intestinal amoebic infections. 8. decompensated liver cirrhosis and hepatitis (alanine aminotransferase (alt) \> 3 times upper limit normal). 9. acute infections (assessed by clinical judgement), supplied with white blood cells (wbc) and c-reactive protein (crp)). 10. rheumatoid arthritis with symptoms or signs of active joint inflammation. 11. pregnancy and nursing 12. extensive active bleeding necessitating blood transfusion. 13. planned elective surgery during the study. 14. participation in any other clinical study within 3 months prior to screening. 15. intolerance to oral iron treatment. 16. untreated b12 or folate deficiency. 17. other i.v. or oral iron treatment or blood transfusion within 4 weeks prior to screening visit. 18. erythropoetin treatment within 8 weeks prior to screening visit. 19. diagnosis of hepatitis b and/or c, confirmed by appropriate lab test. 20. any other medical condition that, in the opinion of investigator, may cause the patient to be unsuitable for the completion of the study or place the patient at potential risk from being in the study. example, uncontrolled hypertension, unstable ischemic heart disease or uncontrolled diabetes mellitus. 21. history of immunocompromise, including positive hiv test result

Keywords: inflammatory bowel disease iron deficiency iron deficiency anaemia anaemia